Recap: Enanta Pharma Q1 Earnings
Portfolio Pulse from Benzinga Insights
Enanta Pharma (NASDAQ:ENTA) reported Q1 earnings with an EPS of $-1.58, missing estimates by 32.77% against an expected $-1.19. Revenue decreased by $5.58 million from the previous year. Despite a positive performance in the last quarter leading to an 11.52% share price increase, this quarter's results fell short of expectations.
February 07, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enanta Pharma reported a significant miss in Q1 earnings with an EPS of $-1.58 against an estimate of $-1.19 and a revenue decrease from the previous year.
The significant miss in both EPS and revenue compared to estimates and the previous year's performance is likely to negatively impact investor sentiment and the stock price in the short term, especially considering the positive reaction to the last quarter's earnings beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100